Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 4/20 | 0.56 |
| ▸ | RAB9A | P51151 | 3/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | CA12 | O43570 | 4/20 | 0.54 |
| ▸ | CA1 | P00915 | 4/20 | 0.54 |
| ▸ | CA2 | P00918 | 4/20 | 0.54 |
| ▸ | CA7 | P43166 | 4/20 | 0.54 |
| ▸ | CA9 | Q16790 | 4/20 | 0.54 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.54 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.52 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.52 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.50 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.50 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL43683 | 0.87 | NPC1 (0.65) | NPC1RAB9ASMN1; SMN2HTTMAPT | |
| SCHEMBL20085587 | 0.82 | PDCD1 (0.59) | NPC1RAB9ASMN1; SMN2HTTMAPT | |
| SCHEMBL23471093 | 0.82 | NPC1 (0.56) | ELANENPC1RAB9ASMN1; SMN2HTT | |
| SCHEMBL8588666 | 0.81 | CA12 (0.62) | ELANENPC1RAB9ASMN1; SMN2HTT | |
| SCHEMBL867390 | 0.81 | CA12 (0.62) | ELANENPC1RAB9ASMN1; SMN2HTT | |
| SCHEMBL27683331 | 0.80 | RAB9A (0.62) | NPC1RAB9ASMN1; SMN2HTTMAPT | |
| SCHEMBL6233392 | 0.80 | NPC1 (0.62) | NPC1RAB9ASMN1; SMN2HTTMAPT | |
| SCHEMBL30678268 | 0.80 | NPC1 (0.62) | NPC1RAB9ASMN1; SMN2HTTMAPT | |
| SCHEMBL161683 | 0.80 | NPC1 (0.58) | NPC1RAB9ASMN1; SMN2HTTMAPT | |
| SCHEMBL161684 | 0.80 | CA12 (0.67) | NPC1RAB9ASMN1; SMN2HTTMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630497-B2 | Compound having malate dehydrogenase inhibitory activity and pharmaceutical composition for preventing or treating cancer comprising same as active ingredient | DONGGUK UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2026-05-19 | — | — | US | disclosed |
| US-20240199572-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING TYPE 2 DIABETES AND DEMENTIA | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-06-20 | — | — | US | disclosed |
| EP-4308554-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING TYPE 2 DIABETES AND DEMENTIA | The Board of Trustees of the University of Illinois (US) | 2024-01-24 | — | — | EP | disclosed |
| WO-2022197658-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING TYPE 2 DIABETES AND DEMENTIA | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2022-09-22 | — | — | WO | disclosed |
| US-20200031764-A1 | NOVEL COMPOUND HAVING MALATE DEHYDROGENASE INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING SAME AS ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2020-01-30 | — | — | US | disclosed |
| WO-2018164549-A1 | NOVEL COMPOUND HAVING MALATE DEHYDROGENASE INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING SAME AS ACTIVE INGREDIENT | 동국대학교 산학협력단 | 2018-09-13 | — | — | WO | disclosed |
| US-20170137407-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. | 2017-05-18 | — | — | US | disclosed |
| US-20170137407-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. | 2017-05-18 | — | — | US | disclosed |
| US-20170065602-A1 | COMPOUNDS WITH TRPV4 ACTIVITY, COMPOSITIONS AND ASSOCIATED METHODS THEREOF | THE UNIVERSITY OF UTAH | 2017-03-09 | — | — | US | disclosed |
| US-20170065602-A1 | COMPOUNDS WITH TRPV4 ACTIVITY, COMPOSITIONS AND ASSOCIATED METHODS THEREOF | THE UNIVERSITY OF UTAH | 2017-03-09 | — | — | US | disclosed |
| US-20130303539-A1 | COMPOUNDS WITH TRPV4 ACTIVITY, COMPOSITIONS AND ASSOCIATED METHODS THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-11-14 | — | — | US | disclosed |
| US-20130053362-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLKINE, LLC (US) | 2013-02-28 | — | — | US | disclosed |
| US-20130053362-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLKINE, LLC (US) | 2013-02-28 | — | — | US | disclosed |
| US-5693827-A | Treatment of HIV infections and compounds useful therein | UNIROYAL CHEMICAL COMPANY, INC. | 1997-12-02 | — | — | US | disclosed |
| EP-0497816-B1 | TREATMENT OF HIV INFECTIONS AND COMPOUNDS USEFUL THEREIN | UNIROYAL CHEMICAL LTD (CA) | 1995-05-17 | — | — | EP | disclosed |
| US-5268389-A | Containing a benzene ring | UNIROYAL CHEMICAL COMPANY, INC. (US) | 1993-12-07 | — | — | US | disclosed |
| EP-0497816-A1 | TREATMENT OF HIV INFECTIONS AND COMPOUNDS USEFUL THEREIN. | UNIROYAL CHEMICAL LTD (CA) | 1992-08-12 | — | — | EP | disclosed |
| WO-1991005761-A1 | TREATMENT OF HIV INFECTIONS AND COMPOUNDS USEFUL THEREIN | UNIROYAL CHEMICAL LTD./UNIROYAL CHEMICAL LTEE (CA) | 1991-05-02 | — | — | WO | disclosed |
| US-4233055-A | Quaternary ammonioalkanecarboxylic acid anilides as plant growth influencing agents | CIBA-GEIGY CORPORATION (US) | 1980-11-11 | — | — | US | disclosed |
| US-4141718-A | ANTIGROWTH AGENTS FOR PLANTS | CIBA-GEIGY CORPORATION (US) | 1979-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200031764-A1 | NOVEL COMPOUND HAVING MALATE DEHYDROGENASE INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING SAME AS ACTIVE INGREDIENT | MDH2, MDH1, ALDH5A1 | ELANE 3734/4885NPC1 2049/4885RAB9A 2374/4885 |
| US-20130303539-A1 | COMPOUNDS WITH TRPV4 ACTIVITY, COMPOSITIONS AND ASSOCIATED METHODS THEREOF | TRPV4, TRPV3, TRPV2 | ELANE 3756/4885NPC1 470/4885RAB9A 3078/4885 |
| US-20130053362-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | AKT3, PIK3CA, AKT1 | ELANE 1309/4885NPC1 1422/4885RAB9A 726/4885 |
| US-12630497-B2 | Compound having malate dehydrogenase inhibitory activity and pharmaceutical composition for preventing or treating cancer comprising same as active ingredient | MDH2, MDH1, ME2 | ELANE 2370/4885NPC1 2130/4885RAB9A 2748/4885 |
| US-20170137407-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | AKT3, PIK3CA, AKT1 | ELANE 1309/4885NPC1 1422/4885RAB9A 726/4885 |
| US-20240199572-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING TYPE 2 DIABETES AND DEMENTIA | SREBF2, SREBF1, SLC2A2 | ELANE 2289/4885NPC1 17/4885RAB9A 3859/4885 |
| US-20170065602-A1 | COMPOUNDS WITH TRPV4 ACTIVITY, COMPOSITIONS AND ASSOCIATED METHODS THEREOF | TRPV4, TRPV3, TRPV2 | ELANE 3756/4885NPC1 470/4885RAB9A 3078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.